Adiponectin, IL-6 and hsC-RP in Relation to Carotid Intima-media Thickness in B-thalassemia Patients
NCT03170245 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85
Last updated 2021-02-16
Summary
Every year, 100,000 neonates are born with hemoglobinopathies around the world. Thalassemia is the most common heterogeneous disease of the human being . It is a disease of high prevalence in Mediterranean, Indian, North Chinese, and Pacific populations. Recently, the quantity and quality of the life of these patients have been significantly improved by regular transfusion and iron chelating therapy .
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Interleukin-6
serum samples used for doing the test by ELISA
- DIAGNOSTIC_TEST
-
HsC-RP
serum samples used for doing the test by ELISA
- DIAGNOSTIC_TEST
-
Adiponectin level
serum samples used for doing the test by ELISA
- DIAGNOSTIC_TEST
-
Carotid intima media thickness
Done by carotid doppler
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-08-01
- Primary Completion
- 2021-01-30
- Completion
- 2021-02-15
Countries
- Egypt
Study Locations
More Related Trials
-
Correlation Between Pulmonary Functions and Physical Fitness in Children With β-thalassemia
NCT05494333 ·Status: UNKNOWN
-
Sexual Maturation in β-Thalassemia Major Patients in Assiut University Hospital
NCT03847558 ·Status: UNKNOWN
-
Assessment of Quality of Life in Thalassemic Patients at Assiut University Hospital: A Single-center Experience
NCT05790980 ·Status: UNKNOWN
-
Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
NCT01443312 ·Status: COMPLETED
-
Erythrocyte Glutamine Level Relation to Pulmonary Hypertension Risk in Beta Thalassemia Major Children
NCT03133169 ·Status: COMPLETED
-
Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
NCT01125254 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Cystatin c and Beta 2 Microglobulin in Thalassemic Children.
NCT03881917 ·Status: UNKNOWN
-
Iron Status in BTM With Blood Transfusion
NCT04947540 ·Status: UNKNOWN
-
Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases
NCT04526405 ·Status: COMPLETED
-
Dermatological Abnormalities in Beta-thalassemia Major
NCT03894605 ·Status: UNKNOWN
-
Evaluation of Nutritional Status in Thalassemia Major Patients in Assiut Children Hospital
NCT03161899 ·Status: COMPLETED
-
Body Composition in Pediatric Patients With Thalassemia Major
NCT07204015 ·Status: NOT_YET_RECRUITING
-
Congenital Heart Surgery in Pediatric Patients With Beta-Thalassemia Major
NCT04367701 ·Status: COMPLETED
-
B-Thalasaemia Trait and Its Possible Cardioprotective Role
NCT02428023 ·Status: UNKNOWN
-
Assessment of Pain in People With Thalassemia
NCT00872339 ·Status: COMPLETED
-
Thalassemia Treatment Based on the Stem Cell Technology
NCT03222453 ·Status: UNKNOWN ·Phase: NA
-
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
NCT00512226 ·Status: COMPLETED ·Phase: NA
-
Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox
NCT03358498 ·Status: UNKNOWN
-
Zinc Supplementation in Patients With β-Thalassemia Major Complicated With Diabetes Mellitus
NCT03851055 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of Cognitive Functions, Psychological Symptoms, and Quality of Life Among B Thalassemia Patients and Their Clinical Correlates.
NCT05105659 ·Status: UNKNOWN
-
Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia
NCT00972231 ·Status: COMPLETED
-
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia
NCT00512564 ·Status: COMPLETED
-
NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
NCT05777733 ·Status: UNKNOWN ·Phase: PHASE1
-
A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
NCT06772766 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
NCT00171171 ·Status: COMPLETED ·Phase: PHASE3